Key Drivers
- Liquidity Cushion
- Persistent Losses
- High Leverage
AIAI Summary
CELC has evolved into a late-stage, catalyst-driven biotech story with real gedatolisib validation from VIKTORIA-1 and a larger addressable market ahead, but the stock remains a high-risk hold until upcoming ASCO/VIKTORIA-2 data prove durability and management avoids dilution from ongoing cash burn.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Persistent Losses
- •High Leverage
CELC has strong liquidity and a sizable cash/investment cushion, but ongoing revenue-free losses, heavy cash burn, high debt, and shrinking equity make the stock look highly stretched.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Rebound demand
- •Resistance zone
CELC's chart remains in a recovering uptrend with higher lows and a rebound after a sharp early-May pullback, but it still needs a clean break above $139-$145 to confirm stronger momentum.
Sharp drop from $144.98 on 2026-05-04 to a mid-May low, followed by a quick rebound to $137.68
Sentiment & News
Key News Insights:
- •Phase 3 win
- •Trial expansion
- •Launch spending
Celcuity's gedatolisib is gaining momentum after Phase 3 VIKTORIA-1 hit its primary endpoint, while the company expands late-stage enrollment and advances launch readiness despite higher Q1 losses.
The news is moderately positive for Celcuity, as clinical progress and broader trial scope strengthen the gedatolisib story even as commercialization costs weigh on near-term results
Similar Companies in Healthcare
Other companies in the same sector with AI ratings